Navigation Links
Cardiologists and Cardiac Surgeons Perform First Trans-catheter Aortic Valve Replacement at Loma Linda University Medical Center

LOMA LINDA, CA. (PRWEB) November 21, 2013

A joint team of cardiologists, cardiac and vascular surgeons and cardiac anesthesiologists completed the first trans-catheter aortic valve replacement (TAVR) at Loma Linda University Medical Center (LLUMC) on Oct. 28, and the patient is doing well. LLUMC is the first hospital in the Inland Empire to perform this type of procedure.

This new therapy is used to treat certain patients who are symptomatic with severe aortic valve stenosis, shortness of breath, chest pain, heart failure, light-headedness, and syncope. TAVR provides an alternative to open heart surgery for patients who are considered inoperable.

The team consisted of cardiologists Anthony Hilliard, MD, and Kenneth Jutzy, MD; cardiothoracic surgeons Anees Razzouk, MD, and Rosario Floridia, MD; vascular surgeon Ahmed Abou-Zamzam, MD; Jason Gatling, MD, and Ryan Lauer, MD from anesthesia and echocardiographers Ramesh Bansal, MD, and Ramdas Pai, MD.

"This procedure requires the collaboration of cardiologists and cardiac surgeons to evaluate and select patients in order to provide the best outcomes," said Dr. Razzouk, chief of cardiothoracic surgery at LLUMC. "Loma Linda University Medical Center was selected as the site to do this procedure, partially because our traditional approach to patient care has been a team approach, especially when it comes to cardiac patients. We work daily with cardiologists and other professionals to present the best options of care for our patients."

Typically, aortic valve replacement (AVR) can be lifesaving for patients with symptomatic aortic stenosis, however the process would normally involve opening the chest, stopping the heart and placing the patient on a cardiopulmonary bypass machine.

Because of the invasive nature of this approach, about 30% of patients with severe aortic stenosis who also have concomitant comorbidities are not considered surgical AVR candidates and would likely not survive beyond two years after symptom onset.

“With TAVR, patients can receive the treatment they need and experience a better quality of life,” said Dr. Jutzy, head of the department of cardiology.

TAVR is a nonsurgical approach that yields survival benefits equivalent to conventional AVR surgery but with shorter procedure times and reduced anesthesia requirements. The procedure involves replacing a narrowed aortic valve using less invasive catheter-based techniques, and the new valve is attached to a catheter inserted into the aorta. Procedure time for TAVR is generally two to three hours.

The TAVR program at Loma Linda University International Heart Institute includes a comprehensive team approach to assessment and treatment involving all participating departments. The team includes an intake coordinator, interventional cardiologists, cardiothoracic surgeons, cardiac anesthesiologists, echocardiographers, radiology professionals, vascular surgeons, nurses and technologists specially trained in TAVR protocols.

For more information on the TAVR procedure, please call 1-855-LLU-VALVE (855-558-8258) or e-mail TAVR(at)llu(dot)edu.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Local Medical Marketing for Cardiologists Now Comes with Performance Guarantees
2. Pets a Boon for the Human Heart, Cardiologists Say
3. Mobile Health Apps & Solutions Market (Cardiac Monitoring, Diabetes Management Devices) Worth $20.7 Billion by 2018 - New Report by MarketsandMarkets
4. New study reports on the high cost of cardiac surgery healthcare associated infections
5. Study questions hypothermia treatment for cardiac arrest
6. Effect of lowering of body temperature for adults with cardiac arrest prior to hospital arrival
7. New Study Reports on the High Cost of Cardiac Surgery Healthcare Associated Infections
8. Northern California Medical Associates (NCMA) Welcomes Jaime Molden, M.D. Cardiac Electrophysiologist to the NCMA Cardiovascular Services Team
9. Hospitalized children more likely to die after cardiac arrest during night shift
10. Allegheny General Hospital Streamlines Testing for Liver Transplant Patients with Advanced Cardiac MRI
11. Researchers at Pace University Explore the Lived Experiences of Families Members That Have the Possible Risk of Genetic Mutations That Cause Sudden Cardiac Death
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... For the millions of people who use ... launched the VaPro Plus Pocket™ touch free hydrophilic intermittent catheter. “Hollister Continence Care ... portfolio,” said Michael Gresavage, Vice President North America. "We designed our VaPro Plus ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , ... control over customization, the possibilities are truly endless, all with a click of a ... position, vertical flip, horizontal flip, depth of field and more, all within Final Cut ...
(Date:11/30/2015)... ... November 30, 2015 , ... Third ... today that it has officially launched a sleek, mobile-ready and user-centric redesigned website. ... company’s new website clearly outlines the benefits that its SEO services provide to ...
(Date:11/30/2015)... ... , ... The National Association of Professional Women (NAPW) honors ... Circle. She is recognized with this prestigious distinction for leadership in estate sales and ... than 850,000 members and over 200 operating Local Chapters. , “I’m pleased to welcome ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , December 1, 2015 ... Injectables, Topical Contraceptives, Male Condoms, Female Condoms, ... Rings, Contraceptive Diaphragms, Contraceptive Sponges, Non-Surgical Permanent ... Share, Growth, Trends and Forecast 2014 - ... Market Research (TMR).The report states that the ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
(Date:12/1/2015)... , Dec. 1, 2015  InCarda Therapeutics, Inc. (InCarda), ... commercialization of therapies for cardiovascular conditions via the inhalation ... business in Australia . InCarda is ... Australia in the first half ... and medical centers in Adelaide ...
Breaking Medicine Technology: